| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_20144e6160709e4f32891ca06efdf499
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a758b53203d20233f50f442b0b269274
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a8d2107f9e7a7be58c07d0ef9c421e6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_14b02369b953bf4ebd31190c8cb63473 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-4973
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-4926
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-494
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-9789
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q19-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61Q19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61Q19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-97 |
| filingDate |
1998-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_736122adffb2a4cd7731727093ee5c09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21cbbe047f33e619b23cc55ad7e480b0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_039c5763e7105ee01e7aa11ca3c5c431 |
| publicationDate |
1998-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9843672-A1 |
| titleOfInvention |
Melaninization inhibitor, skin-care preparation, and bath agent |
| abstract |
A melaninization inhibitor and a skin preparation which has an excellent function of preventing chromatosis caused by inflammation through selective inhibition of irritation of melanocytes by histamine. The above function can be attained by using either a histamine H2 receptor antagonist capable of selectively blocking a histamine H2 receptor or the histamine H2 receptor antagonist in combination with at least one member selected from among histamine liberation inhibitors and histamine H3 receptor agonists. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0113952-A1 |
| priorityDate |
1997-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |